SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
NEW YORK, Feb. 14, 2018 --
The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired common stock of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) between June 24, 2014 and January 4, 2018. You are hereby notified that Levi & Korsinsky has commenced the class action Khanna v. Ohr Pharmaceutical, Inc. (Case No. 1:18-cv-01284) in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra-d/ohr-pharmaceutical-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that (1) Ohr’s lead product Squalamine would not produce vision improvements and was commercially not viable; and (2) as a result of the foregoing, Defendants’ statements about Ohr’s business, operations, and prospects were misleading and/or lacked a reasonable basis.
On January 5, 2018, Ohr announced topline data from its MAKO study to evaluate the use of Squalamine combination therapy for the treatment of wet-AMD. Ohr announced the MAKO study did not meet its primary efficacy endpoint. Following this news, shares of Ohr fell from a close of $2.02 on January 4, 2018, to a close of $0.38 on January 5, 2018.
If you suffered a loss in Ohr you have until April 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
